SLC10A2 and Cholestatic liver disease: By reducing gut-derived BAs entering the liver, IBAT inhibitors may potentially reduce the liver damage in cholestatic liver disease, and IBAT inhibitors, such as maralixibat and odevixibat, are in clinical programs for treating pediatric cholestatic liver diseases (Karpen et al., 2020).